媒體推動實驗的GSK瘧疾疫苗“成功”而不理會致命的副作用

媒體推動實驗的GSK瘧疾疫苗“成功”而不理會致命的副作用
Media pushes 'success' of experimental GSK malaria vaccine while ignoring deadly side effects
Sunday, October 23, 2011
Ethan A. Huff, staff writer
Translation by Autumnson Blog

(NaturalNews) The mainstream media is abuzz with excitement over GlaxoSmithKline's (GSK) latest offering, a malaria trial vaccine that the company claims can cut the risk of clinical and severe malaria in children by 56 percent and 47 percent, respectively. But what GSK and the media are failing to report are the deadly side effects that may accompany the vaccine.
（NaturalNews）主流媒體對葛蘭素史克公司（GSK）的最新產品 - 一種瘧疾的試驗疫苗 - 興奮得議論紛紛，該公司聲稱可以減少臨床風險和兒童中嚴重的瘧疾，分別是56％和47％。但葛蘭素史克和媒體都未有報導可能伴隨著疫苗的致命副作用。
Unveiled at the Bill & Melinda Gates Foundation's recent Malaria Forum conference in Seattle, Wash., the results of the Phase III African study on the malaria vaccine, known as RTS,S, suggest that children who receive three doses of it can derive additional protection against malaria when used in conjunction with other disease control methods. But the findings also show that vaccinated children are at a high risk of serious injury or death as well.
在比爾和梅林達蓋茨基金會最近在華盛頓州西雅圖市的瘧疾論壇會議上揭盅，第三期非洲的瘧疾疫苗研究結果，被稱為 RTS，建議接受三個劑量的孩子們，當與其它疾病的控制方法相結合使用時，可以從中獲得防治瘧疾的額外保護。但研究結果還表明，接種了疫苗的兒童是有嚴重受傷或死亡的高風險。
A report by EarthTimes explains that the full gamut of long term side effects associated with RTS,S will not be known until at least the end of 2014. It also states that "serious adverse events (very serious side effects) for [RTS,S] are around the same level as in those who were given a control drug" (http://www.earthtimes.org/health/ma...). But what exactly was the control drug, and what are these "same level" side effects?
一篇由EarthTimes的報導解釋，與RTS關聯的全域長期副作用，是不到至少2014年年底是不會知的。它還申明“嚴重的不良事件]（非常嚴重的副作用）[RTS，S]是約在同一水平如那些那些被給予控制藥物的”（http://www.earthtimes.org/health/malaria-vaccine-closer-succesful-trial/1527/）。 但究竟什麼是控制藥物，而這些“同一水平”的副作用是什麼？
A quick look at the study results, which have been published in the New England Journal of Medicine, explain that children in the "control" group received a "non-malaria comparator vaccine" (http://www.nejm.org/doi/full/10.1056/NEJMoa1102287). Those five to 17 months of age got a rabies vaccine (VeroRab, Sanofi-Pasteur), and younger children six to 12 weeks of age received a meningococcal serogroup C conjugate vaccine (Menjugate, Novartis).

Both of these vaccines carry with them their own list of side effects, which means they really do not qualify as a legitimate study of "controls." But hardly anyone is paying much attention to this because they are too busy lauding praise on GSK for developing the vaccine and allegedly expecting to make no profit from it.

It all sounds so wonderful and humanitarian, but the fact of the matter is that nearly 18 percent of children in the older vaccinated group suffered serious adverse events from the vaccine, while more than 13 percent in the youngest group suffered the same. And more than 150 children from both groups died during the study (http://www.nejm.org/doi/full/10.1056/NEJMoa1102287).

And since very little is known about how the vaccine affects fertility, neurological function, bodily organs, immunity, and many other aspects of health and well-being in the long term, it is hardly a time to be celebrating.


http://www.naturalnews.com/033951_malaria_vaccine.html